- Latest Stories
- Commentary and Analysis
1:55PM ET 6/10/2022 MT NewswiresCFRA, an independent research provider, has provided MT Newswires with the following research alert. Analysts at CFRA have summarized their opinion as...
10:15AM ET 6/06/2022 MT NewswiresNeurocrine Biosciences (NBIX) has an average rating of outperform and price targets ranging from $75 to $150, according to analysts polled by Capital IQ....
3:04AM ET 5/25/2022 MT NewswiresNeurocrine Biosciences (NBIX) entered into privately negotiated transactions to repurchase about $179.4 million of its existing 2.25% convertible senior...
3:42AM ET 5/13/2022 MT NewswiresNeurocrine Biosciences (NBIX) said late Thursday the US Food and Drug Administration granted an orphan drug designation to valbenazine for the potential...
5:41PM ET 5/11/2022 MT NewswiresRichard F Pops, Director, on May 09, 2022, sold 15,000 shares in Neurocrine Biosciences (NBIX) for $1,144,463. Following the Form 4 filing with the SEC,...
12:39PM ET 5/04/2022 MT NewswiresExpected Earnings Release: 05/04/2022, After-hours Avg. Extended-Hours Dollar Volume: $11,976,203 Neurocrine Biosciences (NBIX) is due to issue its...
11:45AM ET 5/04/2022 MT Newswires(MT Newswires covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may...
8:38AM ET 5/04/2022 MT NewswiresNeurocrine Biosciences (NBIX) reported Wednesday Q1 non-GAAP earnings of $0.30 per share, compared with $0.50 a year earlier. Analysts polled by Capital IQ...
7:38AM ET 5/04/2022 MT Newswires ...
7:37AM ET 5/04/2022 MT Newswires ...